http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7018652-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef200a0e0c65e352fdce3e3b506d3434 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-355 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-355 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 |
| filingDate | 2003-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d387ae71b3597d819bcb574bb897fb1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe2b13e7ad2f73e8df52308d10d78870 |
| publicationDate | 2006-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-7018652-B2 |
| titleOfInvention | Composition and method for treating nonalcoholic steatohepatitis |
| abstract | Nonalcoholic steatohepatitis (NASH) is a disease of the liver characterized by inflammation and damage to the liver cells. Typically, steatohepatitis involves inflammation of the liver related to fat accumulation, and mimics alcoholic hepatitis but is observed in patients who seldom or never consume alcohol. Nonalcoholic steatohepatitis can lead to serious liver damage, and ultimately cirrhosis. The present invention provides methods and compositions useful for the treatment or alleviation of nonalcoholic steatohepatitis and the pharmaceutical formulations for their administration to a human. Specifically, compositions comprised of lecithin, antioxidants and vitamin B complex are administered parenterally, most preferably by oral administration. Specific therapeutic formulations include admixtures of these compounds and specific dosage formulations include daily oral administrations of these compounds in tablet or powder forms. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008201334-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013184892-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013040324-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004030673-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9481861-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011231324-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9763974-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021059275-A1 |
| priorityDate | 1998-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.